<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04417036</url>
  </required_header>
  <id_info>
    <org_study_id>19999</org_study_id>
    <secondary_id>2019-001078-27</secondary_id>
    <nct_id>NCT04417036</nct_id>
  </id_info>
  <brief_title>This Study Collects Information on the Safety of Inhaled Pegylated Adrenomedullin (PEG-ADM), How the Drug is Tolerated and How it Effects Patients Suffering From a Type of Lung Failure That Cause Fluid to Build up in the Lungs Making Breathing Difficult (ARDS)</brief_title>
  <official_title>Safety and Efficacy of Inhaled Pegylated Adrenomedullin (PEG-ADM) in Patients Suffering From Acute Respiratory Distress Syndrome (ARDS): a Double-blind, Randomized, Placebo-controlled, Multicenter Phase 2a/b Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is composed of two parts. In part A of the study two active doses of inhaled
      pegylated adrenomedullin (PEG-ADM) will be compared regarding safety and efficacy to a
      substance that has no therapeutic effect (placebo) in order to find an optimal and safe of
      the study drug. In part B of the study the highest dose that is considered safe and has
      demonstrated efficacy will be taken forward to collect information how well patients
      suffering from Acute Respiratory Distress Syndrome (ARDS) respond to treatment with inhaled
      pegylated adrenomedullin (PEG-ADM) compared to treatment with placebo. ARDS is a type of lung
      failure that cause fluid to build up in the lungs making breathing difficult or impossible.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VFS in Part B participants</measure>
    <time_frame>At Day 28</time_frame>
    <description>Ventilator-free survival (VFS, participants alive and not on invasive mechanical ventilation)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CUI in Part A participants</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Clinical Utility Index (CUI) is a summary measure used to compare different treatments, the index score will range between 0 and 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VFS in Part A participants</measure>
    <time_frame>At Day 28</time_frame>
    <description>Ventilator-free survival (VFS, participants alive and not on invasive mechanical ventilation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality in Part A and Part B participants</measure>
    <time_frame>At Day 28, Day 60 and Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who still require invasive mechanical ventilation support in Part A and Part B participants</measure>
    <time_frame>At Day 28 and Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days (VFDs) in Part A and Part B participants</measure>
    <time_frame>Within Day 28 and Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VFS in Part A and Part B participants</measure>
    <time_frame>At Day 60</time_frame>
    <description>Ventilator-free survival (VFS, participants alive and not on invasive mechanical ventilation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Integrated analysis on VFS invoving all participants from Part A and Part B</measure>
    <time_frame>At Day 28 and Day 60</time_frame>
    <description>Ventilator-free survival (VFS, participants alive and not on invasive mechanical ventilation)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">466</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Part A - Active Drug Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Active Drug Dose 1 for a maximum of 14 days in study phase Part A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - Active Drug Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Active Drug Dose 2 for a maximum of 14 days in study phase Part A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive Placebo for a maximum of 14 days in study phase Part A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B - Active Drug Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Active Drug 1 or 2 for a maximum of 14 days in study phase Part B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive Placebo for a maximum of 14 days in study phase Part B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1097761 Active Dose 1</intervention_name>
    <description>Participants will receive a lower dose ADM by inhalation</description>
    <arm_group_label>Part A - Active Drug Dose 1</arm_group_label>
    <arm_group_label>Part B - Active Drug Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo to BAY1097761</intervention_name>
    <description>Participants will receive Placebo to BAY1097761 by inhalation</description>
    <arm_group_label>Part A - Placebo</arm_group_label>
    <arm_group_label>Part B - Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1097761 Active Dose 2</intervention_name>
    <description>Participants will receive a higher dose ADM by inhalation</description>
    <arm_group_label>Part A - Active Drug Dose 2</arm_group_label>
    <arm_group_label>Part B - Active Drug Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 years of age at the time of inclusion into study.

          -  Invasively mechanically ventilated acute respiratory distress syndrome [ARDS] patients
             (diagnosed according to Berlin definition of ARDS, including positive end-expiratory
             pressure [PEEP] of ≥5 cm H2O, X-ray (or CT scan) indicative of ARDS: bilateral
             opacities not fully explained by cardiac failure, fluid overload, lobar/lung collapse,
             effusions or nodules).

          -  Initial diagnosis of mild, moderate or severe ARDS prior to study inclusion, with
             acute onset of ARDS within 1 week after suspected trigger factor of

               -  Pneumonia

               -  Aspiration

               -  Sepsis

               -  Pancreatitis

          -  Prior to randomization, hypoxemia with PaO2:FiO2 ≤300 mmHg continuously observed for a
             period of ≥4 hours (with values of ≥2 arterial blood gas [ABG] analyses during that
             time, with the last value obtained timely (generally ≤3 hours) prior to
             randomization), under ventilation with minimum PEEP ≥8 cm H2O.

          -  Time from first meeting the last diagnostic ARDS criterion (Berlin criteria) to
             randomization must be ≤48 hours.

          -  For Study Part A: ARDS patients for whom measurements of extra-vascular lung water are
             regarded as medically indicated by the treating physician, and these measurements are
             planned as part of their clinical care, from Study Day 1 up to Study Day 7 (if then
             still intubated).

        Exclusion Criteria:

          -  Any value of a PaO2:FiO2 ratio &gt;300 mmHg within a time interval of 4 hours before
             randomization

          -  Rescue therapy (e.g. inhalation of nitric oxide gas and/or inhalation of prostacyclin
             analogues, or extra corporeal membrane oxygenation [ECMO] / extra corporeal CO2
             removal [ECCO2R]) already initiated at screening and/or Study Day 1 (prior to first
             dose of the study intervention)

          -  Moribund participants not expected to survive 24 hours (clinical decision)

          -  Expected duration of invasive mechanical ventilation less than 48 hours (clinical
             decision)

          -  History of co-morbidities requiring long-term/home oxygen use (e.g. severe chronic
             obstructive pulmonary disease [COPD], pulmonary fibrosis) or non-invasive ventilation
             (except for sleep apnea management), or making weaning per se improbable (e.g. ALS,
             muscular dystrophy)

          -  Smoke inhalation injury, extensive burns or trauma/head injury as concomitant
             condition

          -  History of pneumectomy, lung lobectomy or lung transplant

          -  Diffuse alveolar hemorrhage from vasculitis

          -  Current lung malignancy (incl. lung metastasis), or other malignancy requiring
             chemotherapy or radiation within the last month

          -  Chronic kidney disease with a history of renal replacement therapy (e.g. dialysis)

          -  Chronic liver disease Child-Pugh Class C

          -  Chronic heart failure NYHA IV

          -  Known hypersensitivity to polyethyleneglycol (PEG, Macrogol)

          -  Participation in other interventional studies involving pharmacological interventions,
             or biological or cell therapy interventions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <phone>(+)1-888-84 22937</phone>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum Campus III</name>
      <address>
        <city>Linz</city>
        <state>Oberösterreich</state>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Graz</name>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus der Stadt Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Kralovske Vinohrady</name>
      <address>
        <city>Praha 10</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masaryk Hospital Usti n/L</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>401 13</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover (MHH)</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg AöR</name>
      <address>
        <city>Oldenburg</city>
        <state>Niedersachsen</state>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Köln gGmbH - Krankenhaus Merheim</name>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Santi Paolo e Carlo</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporació Sanitària Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ciutat Sanitària i Universitaria de la Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i de Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 29, 2020</study_first_submitted>
  <study_first_submitted_qc>June 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA &quot;Principles for responsible clinical trial data sharing&quot;. This pertains to scope, timepoint and process of data access.
As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.
Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

